Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, has announced the pricing of its initial public offering of 13,125,000 shares of common stock at an initial public offering price of US$16.00 per share. All shares of common stock are being offered by Alumis. In addition, Alumis has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,968,750 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares began trading on Nasdaq on June 28, 2024, under the symbol “ALMS.” The offering is expected to close on July 1, 2024, subject to the satisfaction or waiver of customary closing conditions.
Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by Orange County/Bay Area partners Shayne Kennedy and Ross McAloon, with associates Jacob Walsh, Kennedy Holmes, and Lexi Zintel.